Narrative Review of Treatment Efficacy of Urge Urinary Incontinence

Urge urinary incontinence (UUI) affects 22% of US women, most over age 60, and is associated with falls, fractures, depression, social isolation, sleep disruption, and earlier nursing home admission. Annual US costs exceed $65 billion, much borne by women through pads, medications, UTIs, clinic visits, and lost work time. Insurance-driven management progresses from behavioral therapy to pharmacotherapy to procedures, yet early steps have the weakest evidence while the best-studied therapies come last, leaving women on prolonged ineffective treatment. This review evaluates whether efficacy evidence supports this sequence. We conducted a structured search of PubMed, MEDLINE via EBSCO, Embase, and Cochrane for publications from 1988 to 2026, using keywords including bladder training, pelvic floor therapy, β3-agonists, antimuscarinics, botulinum toxin, and sacral and tibial neuromodulation. Studies of other incontinence types or pediatric populations were excluded, yielding 32 sources. Bladder training is rarely studied alone. Across 31 studies of 1,817 women, pelvic floor muscle training (PFMT) efficacy ranged 8–75% with consistent use. Within one year, 91% of 31,754 patients discontinued antimuscarinics and 68% of 19,485 discontinued β3-agonists for poor efficacy or adverse effects. Additional therapy was sought by 75% of drug-only patients (40/53) versus 14% with PFMT (8/57). OnabotulinumtoxinA showed 74% efficacy lasting ~6 months. In an RCT (n=190/group), onabotulinumtoxinA reduced daily UUI episodes slightly more than sacral neuromodulation (SNM) over 6 months (3.9 vs 3.3) with more UTIs (35% vs 11%) and self-catheterization. Meta-analyses reported 73.9% efficacy for SNM (n=1,416) and 79.4% for tibial neuromodulation (iTNM; n=350). Early-line treatments have limited, inconsistent evidence and high discontinuation, while procedural therapies show higher, more durable efficacy. Botulinum toxin achieved the highest satisfaction. SNM and iTNM had similar efficacy; SNM lasts up to 15 years, iTNM 3 years with monthly maintenance. Future studies should compare costs and QALYs of insurance-mandated step therapy versus earlier procedures.